Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8911956 | 0.98 | DRD2 (0.51) | DRD2DRD3 | |
| SCHEMBL325236 | 0.91 | — | — | |
| SCHEMBL29921134 | 0.84 | TAAR1 (0.64) | — | |
| SCHEMBL1992016 | 0.84 | TAAR1 (0.64) | — | |
| SCHEMBL12609871 | 0.83 | — | — | |
| SCHEMBL12609873 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL1995859 | 0.83 | TAAR1 (0.63) | — | |
| SCHEMBL134338 | 0.83 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL503067 | 0.83 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL503006 | 0.83 | DRD2 (0.54) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113135835-A | Method for exciting C-C bond breaking acylation and application | 广州中医药大学(广州中医药研究院) | 2021-07-20 | — | — | CN | claimed |
| US-4714699-A | CNS AGENTS | SOCIETE ANONYME DITE: LABORATOIRE L. LAFON (FR) | 1987-12-22 | — | — | US | claimed |
| EP-0138716-B1 | 2-TOLYL-MORPHOLINE DERIVATIVES FOR THERAPEUTICAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1987-08-12 | — | — | EP | claimed |
| EP-0138716-A2 | 2-Tolyl-morpholine derivatives for therapeutical use | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1985-04-24 | — | — | EP | claimed |
| CN-117402124-A | Aryl sulfonamide compound and anti-influenza application thereof | 中国医学科学院医药生物技术研究所 | 2024-01-16 | — | — | CN | disclosed |
| WO-2023078392-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| CN-113135835-B | Method for exciting C-C bond breaking acylation and application | 广州中医药大学(广州中医药研究院) | 2022-07-01 | — | — | CN | disclosed |
| WO-2022000031-A1 | NOVEL COMPOUNDS | Pakinax Pty Ltd (AU) | 2022-01-06 | — | — | WO | disclosed |
| CN-113135835-A | Method for exciting C-C bond breaking acylation and application | 广州中医药大学(广州中医药研究院) | 2021-07-20 | — | — | CN | disclosed |
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | INDIVIOR UK LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | INDIVIOR UK LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-4714699-A | CNS AGENTS | SOCIETE ANONYME DITE: LABORATOIRE L. LAFON (FR) | 1987-12-22 | — | — | US | disclosed |
| US-4714699-A | CNS AGENTS | SOCIETE ANONYME DITE: LABORATOIRE L. LAFON (FR) | 1987-12-22 | — | — | US | disclosed |
| US-4714699-A | CNS AGENTS | SOCIETE ANONYME DITE: LABORATOIRE L. LAFON (FR) | 1987-12-22 | — | — | US | disclosed |
| EP-0138716-B1 | 2-TOLYL-MORPHOLINE DERIVATIVES FOR THERAPEUTICAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1987-08-12 | — | — | EP | disclosed |
| EP-0138716-B1 | 2-TOLYL-MORPHOLINE DERIVATIVES FOR THERAPEUTICAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1987-08-12 | — | — | EP | disclosed |
| EP-0138716-A2 | 2-Tolyl-morpholine derivatives for therapeutical use | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1985-04-24 | — | — | EP | disclosed |
| EP-0138716-A2 | 2-Tolyl-morpholine derivatives for therapeutical use | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1985-04-24 | — | — | EP | disclosed |
| EP-0138716-A2 | 2-Tolyl-morpholine derivatives for therapeutical use | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | DRD3, DRD2, SLC6A3 | DRD2 2/4885DRD3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.